{"id":"W2888480300","doi":"10.1093/annonc/mdy245","title":"Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"National Medical Research Council; Imperial Experimental Cancer Medicine Centre; Public Health Agency; King’s College London; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust; Institute of Cancer Research; National Institute on Handicapped Research; Christie NHS Foundation Trust; AstraZeneca","keywords":"Medicine; Paclitaxel; Serous fluid; Ovarian cancer; Serous ovarian cancer; Oncology; Lung cancer; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005504731,0.0003880609,0.001000706,0.0003186527,0.000231214,0.0004147913,0.0003325595,0.0002703771,0.0006218757],"category_scores_gemma":[0.0005917693,0.0002068646,0.0004435124,0.0004492109,0.0002476816,0.0002782482,0.000218048,0.0006839302,0.0001365052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007209061,"about_ca_system_score_gemma":0.0007854683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008042342,"about_ca_topic_score_gemma":0.00352376,"domain_scores_codex":[0.9998197,0.00008058991,0.00001817878,0.00002648568,0.00002258432,0.00003248496],"domain_scores_gemma":[0.9997571,0.00005680786,0.00006336129,0.0000145126,0.00001382647,0.00009434218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1824221,0.01054312,0.1951618,0.001289997,0.001700295,0.002344279,0.0006956045,0.008729341,0.08120885,0.000257682,0.003999232,0.5116477],"study_design_scores_gemma":[0.0627799,0.2965064,0.579826,0.0001712399,0.00203107,0.005889597,0.0004575753,0.01384775,0.02189704,0.0004672761,0.01603787,0.00008829543],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967789,0.002021871,0.0001223801,0.0001470468,0.00001628134,0.0001534043,0.00009918866,0.00002485723,0.0006360955],"genre_scores_gemma":[0.9979995,0.0008494902,0.0004624401,0.0001218194,0.00002809751,0.00009773475,0.0002350719,0.000003504976,0.0002024041],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001000706,"threshold_uncertainty_score":0.005230546,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01461035700738899,"score_gpt":0.2913217063593029,"score_spread":0.2767113493519139,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}